CN1610676A - 用于治疗膀胱活动过度的化合物和方法 - Google Patents

用于治疗膀胱活动过度的化合物和方法 Download PDF

Info

Publication number
CN1610676A
CN1610676A CNA028265696A CN02826569A CN1610676A CN 1610676 A CN1610676 A CN 1610676A CN A028265696 A CNA028265696 A CN A028265696A CN 02826569 A CN02826569 A CN 02826569A CN 1610676 A CN1610676 A CN 1610676A
Authority
CN
China
Prior art keywords
compound
butyl
dichlorophenyl
piperidino
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028265696A
Other languages
English (en)
Chinese (zh)
Inventor
R·比亚韦茨基
C·丹茨曼
K·赫尔措格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1610676A publication Critical patent/CN1610676A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028265696A 2001-11-02 2002-11-01 用于治疗膀胱活动过度的化合物和方法 Pending CN1610676A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder
SE01037951 2001-11-02

Publications (1)

Publication Number Publication Date
CN1610676A true CN1610676A (zh) 2005-04-27

Family

ID=20285984

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028265696A Pending CN1610676A (zh) 2001-11-02 2002-11-01 用于治疗膀胱活动过度的化合物和方法

Country Status (16)

Country Link
US (1) US7368461B2 (enExample)
EP (1) EP1444220B1 (enExample)
JP (1) JP2005511571A (enExample)
KR (1) KR20040053239A (enExample)
CN (1) CN1610676A (enExample)
AT (1) ATE353886T1 (enExample)
BR (1) BR0213832A (enExample)
CA (1) CA2465429A1 (enExample)
DE (1) DE60218203T2 (enExample)
ES (1) ES2282491T3 (enExample)
IL (1) IL161600A0 (enExample)
MX (1) MXPA04004075A (enExample)
NO (1) NO20042138L (enExample)
SE (1) SE0103795D0 (enExample)
WO (1) WO2003037889A1 (enExample)
ZA (1) ZA200403206B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
CN112915266B (zh) * 2021-02-05 2021-11-09 武汉磁济科技有限公司 一种人工膀胱铁磁复合体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9505084D0 (en) 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
CA2357803A1 (en) * 1998-12-04 2000-06-15 Rimma Iliinichna Ashkinazi Aryl- and heteroarylamides of carboalkoxysulfanilic acids
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
SE0103795D0 (sv) 2001-11-02
CA2465429A1 (en) 2003-05-08
EP1444220B1 (en) 2007-02-14
ZA200403206B (en) 2005-02-22
US20050203113A1 (en) 2005-09-15
IL161600A0 (en) 2004-09-27
WO2003037889A1 (en) 2003-05-08
JP2005511571A (ja) 2005-04-28
ATE353886T1 (de) 2007-03-15
EP1444220A1 (en) 2004-08-11
KR20040053239A (ko) 2004-06-23
ES2282491T3 (es) 2007-10-16
NO20042138L (no) 2004-05-25
MXPA04004075A (es) 2004-07-23
US7368461B2 (en) 2008-05-06
WO2003037889A8 (en) 2004-05-06
DE60218203T2 (de) 2008-01-03
BR0213832A (pt) 2004-08-31
DE60218203D1 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
CN1128789C (zh) 苯并环庚并噻吩化合物
CN1711085A (zh) 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物
CN1085945C (zh) 用作α2肾上腺素能受体兴奋剂的7-(2-咪唑啉基氨基)喹啉化合物
CN1137755A (zh) 用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物
WO2008040974A1 (en) Indoles for use as dpp-iv inhibitors
JPH09512804A (ja) 5−ht1dアンタゴニストとして有用なビフェニルカルボキシアミド類
CN1652787A (zh) 利用δ阿片受体促效药来防止下泌尿系功能障碍的组合物和方法
CN1610676A (zh) 用于治疗膀胱活动过度的化合物和方法
CN102453001B (zh) 硫代吗啉类化合物及其制备方法和用途
CA2770766C (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
US20140350099A1 (en) Method of Treating or Preventing Pain
CN1141940C (zh) 多环噻唑体系用于制备预防或治疗肥胖的药物的用途
WO2007123511A2 (en) Dosing regimens for the treatment of cancer
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
TW201136922A (en) New oxadiazole derivatives
CN1190971A (zh) 三环性苯并氮杂䓬化合物
JPWO2005079845A1 (ja) 片頭痛予防薬
HK1075658A (en) Compounds and method for the treatment of overactive bladder
US20040248914A1 (en) Method for the treatment of overactive bladder
TW201139420A (en) Androgen receptor modulator and uses thereof
HK1076732A (en) Method for the treatment of overactive bladder
CN1346347A (zh) 环胺衍生物和它们的用途
WO2018053587A1 (en) Compositions for the treatment of hypertension and/or fibrosis
AU2002347708A1 (en) Method for the treatment of overactive bladder
AU2002347709A1 (en) Compounds and method for the treatment of overactive bladder

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075658

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075658

Country of ref document: HK